tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Vor Biopharma (VOR) and Prometheus Biosciences (RXDX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Illumina (ILMNResearch Report), Vor Biopharma (VORResearch Report) and Prometheus Biosciences (RXDXResearch Report) with bullish sentiments.

Illumina (ILMN)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Illumina yesterday and set a price target of $300.00. The company’s shares closed last Tuesday at $219.83, close to its 52-week low of $173.45.

According to TipRanks.com, Arias is a 4-star analyst with an average return of 4.8% and a 57.9% success rate. Arias covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Guardant Health, and NanoString Tech.

Currently, the analyst consensus on Illumina is a Hold with an average price target of $258.75, a 15.4% upside from current levels. In a report issued on August 12, Canaccord Genuity also maintained a Buy rating on the stock with a $380.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Vor Biopharma (VOR)

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Vor Biopharma yesterday and set a price target of $21.00. The company’s shares closed last Tuesday at $5.26, close to its 52-week low of $3.83.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 16.5% and a 48.1% success rate. Willey covers the Healthcare sector, focusing on stocks such as Bolt Biotherapeutics, AbCellera Biologics, and SQZ Biotechnologies.

Vor Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $19.00, a 250.7% upside from current levels. In a report issued on August 15, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.

Prometheus Biosciences (RXDX)

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Prometheus Biosciences yesterday and set a price target of $50.00. The company’s shares closed last Tuesday at $48.06, close to its 52-week high of $52.30.

According to TipRanks.com, Samimy is a 4-star analyst with an average return of 6.0% and a 48.4% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Bausch Health Companies, and Jazz Pharmaceuticals.

Prometheus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $57.86, a 18.7% upside from current levels. In a report issued on August 12, RBC Capital also maintained a Buy rating on the stock with a $61.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ILMN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More